Navigation Links
Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting
Date:3/30/2012

AMSTERDAM, The Netherlands, March 30, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the Extraordinary General Meeting (EGM) of shareholders was held in Amsterdam, the Netherlands, today in accordance with the EGM Notice of February 17, 2012. At the EGM, shareholders approved all the resolutions proposed for the substantial corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated.

The shareholders in uniQure previously included a condition to the transaction that meant an additional € 1.0 million of investment was to be secured by AMT prior to completion. This condition has been waived. Completion of the uniQure transaction is expected to occur in early April 2012. Further details on timing on the uniQure transaction are set out on the company's website.

The resolutions put to the EGM convened in accordance with the Notice were passed by a majority in excess of 99 percent. The detailed voting information and results pursuant to Section 2:120 paragraph 5 of the Dutch Civil Code will be posted on the website http://www.amtbiopharma.com.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gen
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
2. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
7. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
8. Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
9. 8th Annual World Health Care Congress Set for Amsterdam, Spring 2012
10. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
11. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Pharmavite LLC announced that Timothy "Tim" ... effective immediately. Toll recently served as Pharmavite,s executive vice ... management, private label and sales administration in ... role, Toll will expand his responsibilities to include international ... "Toll,s appointment to chief customer officer is part of ...
(Date:7/23/2014)... , July 23, 2014 Research ... the "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation ... or destroy faulty electrical pathways from sections of ... known as cardiac arrhythmias). Cardiac arrhythmias can be ...
(Date:7/23/2014)... NEW YORK , July 23, 2014 /PRNewswire/ ... Delray Beach, Fla. , is an emerging ... molecular diagnostic systems for bio-threat detection and rapid ... system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), ... of Homeland Security ("DHS") Science & Technology directorate, ...
Breaking Medicine Technology:Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... 31, 2011 Mevion Medical Systems announced today it ... S. Lee Kling Center for Proton Therapy at the ... University School of Medicine in St. Louis MO. This ... of the first MEVION S250 proton accelerator module and ...
... 31, 2011 Royal Philips Electronics (AEX: PHI, NYSE: ... full-field digital mammography (FFDM) solution that offers a lower ... compromising image quality. The addition of MicroDose to Philips, ... for the company,s focus on women,s health care, and ...
Cached Medicine Technology:Mevion Medical Systems Delivers the World's First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 3Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 4
(Date:7/23/2014)... 2014 The puffiness that can appear ... techniques, according to a new guide published at the ... in the U.S. is now available for men and ... complimentary guide that is now published is meant to ... eye puffiness. While surgical techniques are available, there are ...
(Date:7/23/2014)... or Dounreay since the 1990s are not at an ... in the British Journal of Cancer today* ... at the University of Oxford and from Newcastle University ... who were under 25 and living near Sellafield or ... incidence from 1991-2006 between those living near these nuclear ...
(Date:7/23/2014)... Home Care Assistance of Oklahoma ... for seniors, announces the next installment in its ... a wide range of health and wellness-related fields. ... worker and award-winning author Nancy Kriseman, and will ... and ways to prevent burnout by becoming more ...
(Date:7/23/2014)... Lake Worth, FL (PRWEB) July 23, 2014 ... will take place Aug. 10-16, Millennium Treatment Group is ... Substance abuse has existed in society ever since man ... make wine. Substance abuse treatment has existed since shortly ... of recognizing a problem and then developing a way ...
(Date:7/23/2014)... By Alan Mozes ... -- U.S. servicemen are more likely to have been exposed ... a large, new survey suggests. The finding seems to ... team suggested that the finding could be a cause for ... physical, mental, and/or sexual abuse among the civilian population has ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3
... DIEGO, Feb. 2 MedWaves, Inc. announces the ... Certification. This is in addition to having already ... Company,s patented Microwave Coagulation/Ablation System for surgical applications. ... surgeons and interventional radiologists to treat soft tissue ...
... Full Year Expectations for Revenue GrowthBRAINTREE, Mass., Feb. 2 ... reported third quarter fiscal 2009 GAAP net revenues of ... up 25%; and net earnings per share of $0.62, ... up 18%; operating income is $67 million, up 35%; ...
... study says , , MONDAY, Feb. 2 (HealthDay News) -- ... people who sleep too little or too much, according ... , Previous studies have linked both short and long ... disease, diabetes, obesity, and death. Chronic elevations in inflammation-regulating ...
... Feb. 2 A 74-year-old prostate,cancer patient has become ... a,new, faster form of radiotherapy that extends more advanced ... the faster treatment,using RapidArc radiotherapy technology from Varian Medical ... The patient, a retired military aircraft engineer from ...
... Xmark Opportunity Partners, LLC ("Xmark"), the sole member of the ... Fund, Ltd., has, in the past, sent letters to the ... ) setting forth its dissatisfaction with the company,s corporate governance, ... this opportunity to respond to the Form 8-K filed by ...
... will drive adhesion barrier market, according to Millennium ... According to Millennium Research Group,s (MRG,s) US ... Adhesion Barriers 2009 report, growing surgeon interest ... launches, will fuel revenues in the US adhesion ...
Cached Medicine News:Health News:MedWaves, Inc. Announces Receipt of MDD CE Certification and Additional U.S. FDA 510(k) Clearance to Market Its Patented Microwave Coagulation/Ablation System and Devices 2Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 2Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 3Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 4Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 5Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 6Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 7Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 8Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 9Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 10Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 11Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 12Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 13Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 14Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 15Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 16Health News:Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009 17Health News:Inflammation May Play Role in Sleep Duration 2Health News:Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems 2Health News:Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems 3Health News:Adhesion Barrier Market to Skyrocket to Over $550 Million by 2013 2Health News:Adhesion Barrier Market to Skyrocket to Over $550 Million by 2013 3
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Standard bipolar coagulator...
Medicine Products: